Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...

‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ was published in the Cochrane Database of Systematic Reviews at ...

I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the ...

New biologics, precision diagnostics, and AI are reshaping care for rare allergies — from eosinophilic esophagitis to drug ...

INCA033989 targets CALR mutations, showing efficacy in engineered cell lines and mouse models of MPNs, without affecting other cells. CALR mutations are significant in JAK2V617F-negative essential ...

HONG KONG, Dec. 11, 2022 /PRNewswire/ -- Akeso Inc. (9926. HK) ("Akeso") today announced that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, published the mechanism of action ...

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum ...